Biomarcadores del cáncer (Spanish Wikipedia)

Analysis of information sources in references of the Wikipedia article "Biomarcadores del cáncer" in Spanish language version.

refsWebsite

Global rank Spanish rank

40doi.org

2^nd place

39nih.gov

4^th place

6hematologylibrary.org

low place

5web.archive.org

1^st place

5archive.org

6^th place

5^th place

2pnas.org

1,293^rd place

471^st place

2elsevier.com

610^th place

332^nd place

1mlo-online.com

low place

1cancer.gov

1,684^th place

1,021^st place

1researchadvocacy.org

low place

1oxfordjournals.org

1,389^th place

513^th place

1medscape.com

719^th place

759^th place

1time.com

61^st place

90^th place

1fda.gov

447^th place

668^th place

1cancer.org

3,680^th place

3,012^th place

1asco.org

low place

1clinchem.org

low place

1singularityhub.com

low place

archive.org

«Distinguishing second primary tumors from lung metastases in patients with head and neck squamous cell carcinoma.». Journal of the National Cancer Institute 90 (13): 972-7. 1 de julio de 1998. PMID 9665144. doi:10.1093/jnci/90.13.972.
«Loss of estrogen receptor in recurrent breast cancer is associated with poor response to endocrine therapy.». Journal of Clinical Oncology 14 (9): 2584-9. September 1996. PMID 8823339. doi:10.1200/jco.1996.14.9.2584.
«American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer.». Journal of Clinical Oncology 25 (33): 5287-312. 20 de noviembre de 2007. PMID 17954709. doi:10.1200/JCO.2007.14.2364.
«TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer.». Journal of Clinical Oncology 23 (25): 5892-9. 1 de septiembre de 2005. PMID 16043829. doi:10.1200/JCO.2005.02.840.
«Gastrointestinal stromal tumor markers in cutaneous melanomas: relationship to prognostic factors and outcome». American Journal of Clinical Pathology 136 (1): 74-80. July 2011. PMID 21685034. doi:10.1309/AJCP9KHD7DCHWLMO.

asco.org

Lenz, Heinz-Josef. EdBk.GI.Colo.04.pdf «Established Biomarkers in Colon Cancer» (PDF). American Society of Clinical Oncology’s 2009 Educational Book. (enlace roto disponible en Internet Archive; véase el historial, la primera versión y la última).

cancer.gov

«biomarker». NCI Dictionary of Cancer Terms. National Cancer Institute.

cancer.org

«Tumor Markers Fact Sheet» (PDF). American Cancer Society. Archivado desde el original el 5 de noviembre de 2012. Consultado el 14 de marzo de 2018.

clinchem.org

«A personalized approach to cancer treatment: how biomarkers can help». Clinical Chemistry 54 (11): 1770-9. November 2008. PMID 18801934. doi:10.1373/clinchem.2008.110056.

doi.org

dx.doi.org

Mishra, Alok; Verma, Mukesh (2010). «Cancer Biomarkers: Are We Ready for the Prime Time?». Cancers 2 (1): 190-208. doi:10.3390/cancers2010190.
Behne, Tara; Copur, M. Sitki (1 de enero de 2012). «Biomarkers for Hepatocellular Carcinoma». International Journal of Hepatology 2012: 1-7. doi:10.1155/2012/859076.
Musolino, A; Bella, MA; Bortesi, B; Michiara, M; Naldi, N; Zanelli, P; Capelletti, M; Pezzuolo, D; Camisa, R; Savi, M; Neri, TM; Ardizzoni, A (June 2007). «BRCA mutations, molecular markers, and clinical variables in early-onset breast cancer: a population-based study.». Breast 16 (3): 280-92. PMID 17257844. doi:10.1016/j.breast.2006.12.003.
Dienstmann, R; Tabernero, J (March 2011). «BRAF as a target for cancer therapy.». Anti-Cancer Agents in Medicinal Chemistry 11 (3): 285-95. PMID 21426297. doi:10.2174/187152011795347469.
Lamparella, N; Barochia, A; Almokadem, S (2013). «Impact of genetic markers on treatment of non-small cell lung cancer.». Advances in Experimental Medicine and Biology 779: 145-64. PMID 23288638. doi:10.1007/978-1-4614-6176-0_6.
Orphanos, G; Kountourakis, P (2012). «Targeting the HER2 receptor in metastatic breast cancer.». Hematology/Oncology and Stem Cell Therapy 5 (3): 127-37. PMID 23095788. doi:10.5144/1658-3876.2012.127.
DePrimo, S. E.; Huang, X.; Blackstein, M. E.; Garrett, C. R.; Harmon, C. S.; Schoffski, P.; Shah, M. H.; Verweij, J.; Baum, C. M.; Demetri, G. D. (8 de septiembre de 2009). «Circulating Levels of Soluble KIT Serve as a Biomarker for Clinical Outcome in Gastrointestinal Stromal Tumor Patients Receiving Sunitinib following Imatinib Failure». Clinical Cancer Research 15 (18): 5869-5877. PMC 3500590. PMID 19737953. doi:10.1158/1078-0432.CCR-08-2480.
Kruijff, S; Hoekstra, HJ (April 2012). «The current status of S-100B as a biomarker in melanoma.». European Journal of Surgical Oncology 38 (4): 281-5. PMID 22240030. doi:10.1016/j.ejso.2011.12.005.
Ludwig, JA; Weinstein, JN (November 2005). «Biomarkers in cancer staging, prognosis and treatment selection.». Nature Reviews Cancer 5 (11): 845-56. PMID 16239904. doi:10.1038/nrc1739.
Wang, Qing; Raghothama Chaerkady (December 2010). «Mutant proteins as cancer-specific biomarkers.». Proceedings of the National Academy of Sciences 108: 2444-2449. PMC 3038743. PMID 21248225. doi:10.1073/pnas.1019203108. Consultado el 10 de abril de 2016.
Verma, M; Manne, U (October 2006). «Genetic and epigenetic biomarkers in cancer diagnosis and identifying high risk populations.». Critical Reviews in Oncology/Hematology 60 (1): 9-18. PMID 16829121. doi:10.1016/j.critrevonc.2006.04.002.
«Distinguishing second primary tumors from lung metastases in patients with head and neck squamous cell carcinoma.». Journal of the National Cancer Institute 90 (13): 972-7. 1 de julio de 1998. PMID 9665144. doi:10.1093/jnci/90.13.972.
«High levels of serum TIMP-1 correlate with advanced disease and predict for poor survival in patients with multiple myeloma treated with novel agents». Leukemia Research 34 (3): 399-402. March 2010. PMID 19781774. doi:10.1016/j.leukres.2009.08.035.
«Loss of estrogen receptor in recurrent breast cancer is associated with poor response to endocrine therapy.». Journal of Clinical Oncology 14 (9): 2584-9. September 1996. PMID 8823339. doi:10.1200/jco.1996.14.9.2584.
«American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer.». Journal of Clinical Oncology 25 (33): 5287-312. 20 de noviembre de 2007. PMID 17954709. doi:10.1200/JCO.2007.14.2364.
«Prognostic and predictive effects of immunohistochemical factors in high-risk primary breast cancer patients.». Clinical Cancer Research 12 (1): 159-68. Jan 1, 2006. PMID 16397038. doi:10.1158/1078-0432.CCR-05-1340.
«Efficacy, safety, and pharmacokinetics of imatinib dose escalation to 800 mg/day in patients with advanced gastrointestinal stromal tumors.». Investigational New Drugs 31 (5): 1367-74. Apr 17, 2013. PMID 23591629. doi:10.1007/s10637-013-9961-8.
«Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial.». Lancet 368 (9544): 1329-38. 14 de octubre de 2006. PMID 17046465. doi:10.1016/S0140-6736(06)69446-4.
«TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer.». Journal of Clinical Oncology 23 (25): 5892-9. 1 de septiembre de 2005. PMID 16043829. doi:10.1200/JCO.2005.02.840.
«Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.». The New England Journal of Medicine 350 (21): 2129-39. 20 de mayo de 2004. PMID 15118073. doi:10.1056/NEJMoa040938.
Sawyers CL (April 2008). «The cancer biomarker problem». Nature 452 (7187): 548-52. PMID 18385728. doi:10.1038/nature06913.
«Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyltransferase gene locus». Journal of the National Cancer Institute 91 (23): 2001-8. December 1999. PMID 10580024. doi:10.1093/jnci/91.23.2001.
«Economics of Cancer Biomarkers». Personalized Medicine 9 (8): 829-837. 2012. doi:10.2217/pme.12.87.
«Serum S100--a marker for disease monitoring in metastatic melanoma.». Dermatology 194 (3): 208-12. 1997. PMID 9187834. doi:10.1159/000246103.
«S100 proteins as cancer biomarkers with focus on S100B in malignant melanoma.». Clinical Biochemistry 37 (7): 512-8. July 2004. PMID 15234232. doi:10.1016/j.clinbiochem.2004.05.012.
«Is the 21-gene recurrence score a cost-effective assay in endocrine-sensitive node-negative breast cancer?». Expert Review of Pharmacoeconomics & Outcomes Research 13 (2): 243-50. April 2013. PMID 23570435. doi:10.1586/erp.13.4.
«Impact of Oncotype DX on Treatment Decisions in ER-Positive, Node-Negative Breast Cancer with Histologic Correlation.». The Breast Journal 19 (3): 269-75. May 2013. PMID 23614365. doi:10.1111/tbj.12099.
«Imatinib: a review of its use in chronic myeloid leukaemia.». Drugs 67 (2): 299-320. 2007. PMID 17284091. doi:10.2165/00003495-200767020-00010.
«Gastrointestinal stromal tumor markers in cutaneous melanomas: relationship to prognostic factors and outcome». American Journal of Clinical Pathology 136 (1): 74-80. July 2011. PMID 21685034. doi:10.1309/AJCP9KHD7DCHWLMO.
«Chronic lymphocytic leukaemia CD20 expression is dependent on the genetic subtype: a study of quantitative flow cytometry and fluorescent in-situ hybridization in 510 patients». British Journal of Haematology 141 (1): 36-40. April 2008. PMID 18324964. doi:10.1111/j.1365-2141.2008.07012.x.
«Effective therapy of murine models of human leukemia and lymphoma with radiolabeled anti-CD30 antibody, HeFi-1». Proceedings of the National Academy of Sciences of the United States of America 104 (20): 8444-8. May 2007. PMC 1895969. PMID 17488826. doi:10.1073/pnas.0702496104.
«FIP1L1/PDGFRalpha synergizes with SCF to induce systemic mastocytosis in a murine model of chronic eosinophilic leukemia/hypereosinophilic syndrome». Blood 112 (6): 2500-7. September 2008. PMID 18539901. doi:10.1182/blood-2007-11-126268.
Nimer SD (May 2008). «Myelodysplastic syndromes». Blood 111 (10): 4841-51. PMID 18467609. doi:10.1182/blood-2007-08-078139.
«Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a phase 2 study». Blood 110 (7): 2309-15. October 2007. PMID 17496201. doi:10.1182/blood-2007-02-073528.
«Chemotherapeutic agents circumvent emergence of dasatinib-resistant BCR-ABL kinase mutations in a precise mouse model of Philadelphia chromosome-positive acute lymphoblastic leukemia». Blood 117 (13): 3585-95. March 2011. PMC 3072880. PMID 21263154. doi:10.1182/blood-2010-08-301267.
«Regulation of S100A10 by the PML-RAR-α oncoprotein». Blood 117 (15): 4095-105. April 2011. PMID 21310922. doi:10.1182/blood-2010-07-298851.
«A personalized approach to cancer treatment: how biomarkers can help». Clinical Chemistry 54 (11): 1770-9. November 2008. PMID 18801934. doi:10.1373/clinchem.2008.110056.
«Pharmacogenetic study in Hodgkin lymphomas reveals the impact of UGT1A1 polymorphisms on patient prognosis». Blood 113 (14): 3307-13. April 2009. PMID 18768784. doi:10.1182/blood-2008-03-148874.
«Evaluation of EML4-ALK fusion proteins in non-small cell lung cancer using small molecule inhibitors». Neoplasia 13 (1): 1-11. January 2011. PMC 3022423. PMID 21245935. doi:10.1593/neo.101120.
«New driver mutations in non-small-cell lung cancer». Lancet Oncology 12 (2): 175-80. February 2011. PMID 21277552. doi:10.1016/S1470-2045(10)70087-5.

elsevier.com

linkinghub.elsevier.com

«High levels of serum TIMP-1 correlate with advanced disease and predict for poor survival in patients with multiple myeloma treated with novel agents». Leukemia Research 34 (3): 399-402. March 2010. PMID 19781774. doi:10.1016/j.leukres.2009.08.035.
«New driver mutations in non-small-cell lung cancer». Lancet Oncology 12 (2): 175-80. February 2011. PMID 21277552. doi:10.1016/S1470-2045(10)70087-5.

fda.gov

«Table of Pharmacogenomic Biomarkers in Drug Labels». U.S Food and Drug Administration.

hematologylibrary.org

bloodjournal.hematologylibrary.org

«FIP1L1/PDGFRalpha synergizes with SCF to induce systemic mastocytosis in a murine model of chronic eosinophilic leukemia/hypereosinophilic syndrome». Blood 112 (6): 2500-7. September 2008. PMID 18539901. doi:10.1182/blood-2007-11-126268.
Nimer SD (May 2008). «Myelodysplastic syndromes». Blood 111 (10): 4841-51. PMID 18467609. doi:10.1182/blood-2007-08-078139.
«Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a phase 2 study». Blood 110 (7): 2309-15. October 2007. PMID 17496201. doi:10.1182/blood-2007-02-073528.
«Chemotherapeutic agents circumvent emergence of dasatinib-resistant BCR-ABL kinase mutations in a precise mouse model of Philadelphia chromosome-positive acute lymphoblastic leukemia». Blood 117 (13): 3585-95. March 2011. PMC 3072880. PMID 21263154. doi:10.1182/blood-2010-08-301267.
«Regulation of S100A10 by the PML-RAR-α oncoprotein». Blood 117 (15): 4095-105. April 2011. PMID 21310922. doi:10.1182/blood-2010-07-298851.
«Pharmacogenetic study in Hodgkin lymphomas reveals the impact of UGT1A1 polymorphisms on patient prognosis». Blood 113 (14): 3307-13. April 2009. PMID 18768784. doi:10.1182/blood-2008-03-148874.

medscape.com

«Economics of Cancer Biomarkers». Personalized Medicine 9 (8): 829-837. 2012. doi:10.2217/pme.12.87.

mlo-online.com

Rhea, Jeanne; Ross J. Molinaro (March 2011). «Cancer Biomarkers: Surviving the journey from bench to bedside». Medical Laboratory Observer. Archivado desde el original el 14 de octubre de 2013. Consultado el 26 de abril de 2013.

nih.gov

ncbi.nlm.nih.gov

Musolino, A; Bella, MA; Bortesi, B; Michiara, M; Naldi, N; Zanelli, P; Capelletti, M; Pezzuolo, D; Camisa, R; Savi, M; Neri, TM; Ardizzoni, A (June 2007). «BRCA mutations, molecular markers, and clinical variables in early-onset breast cancer: a population-based study.». Breast 16 (3): 280-92. PMID 17257844. doi:10.1016/j.breast.2006.12.003.
Dienstmann, R; Tabernero, J (March 2011). «BRAF as a target for cancer therapy.». Anti-Cancer Agents in Medicinal Chemistry 11 (3): 285-95. PMID 21426297. doi:10.2174/187152011795347469.
Lamparella, N; Barochia, A; Almokadem, S (2013). «Impact of genetic markers on treatment of non-small cell lung cancer.». Advances in Experimental Medicine and Biology 779: 145-64. PMID 23288638. doi:10.1007/978-1-4614-6176-0_6.
Orphanos, G; Kountourakis, P (2012). «Targeting the HER2 receptor in metastatic breast cancer.». Hematology/Oncology and Stem Cell Therapy 5 (3): 127-37. PMID 23095788. doi:10.5144/1658-3876.2012.127.
DePrimo, S. E.; Huang, X.; Blackstein, M. E.; Garrett, C. R.; Harmon, C. S.; Schoffski, P.; Shah, M. H.; Verweij, J.; Baum, C. M.; Demetri, G. D. (8 de septiembre de 2009). «Circulating Levels of Soluble KIT Serve as a Biomarker for Clinical Outcome in Gastrointestinal Stromal Tumor Patients Receiving Sunitinib following Imatinib Failure». Clinical Cancer Research 15 (18): 5869-5877. PMC 3500590. PMID 19737953. doi:10.1158/1078-0432.CCR-08-2480.
Bantis, A; Grammaticos, P (Sep–Dec 2012). «Prostatic specific antigen and bone scan in the diagnosis and follow-up of prostate cancer. Can diagnostic significance of PSA be increased?». Hellenic Journal of Nuclear Medicine 15 (3): 241-6. PMID 23227460.
Kruijff, S; Hoekstra, HJ (April 2012). «The current status of S-100B as a biomarker in melanoma.». European Journal of Surgical Oncology 38 (4): 281-5. PMID 22240030. doi:10.1016/j.ejso.2011.12.005.
Ludwig, JA; Weinstein, JN (November 2005). «Biomarkers in cancer staging, prognosis and treatment selection.». Nature Reviews Cancer 5 (11): 845-56. PMID 16239904. doi:10.1038/nrc1739.
Wang, Qing; Raghothama Chaerkady (December 2010). «Mutant proteins as cancer-specific biomarkers.». Proceedings of the National Academy of Sciences 108: 2444-2449. PMC 3038743. PMID 21248225. doi:10.1073/pnas.1019203108. Consultado el 10 de abril de 2016.
Verma, M; Manne, U (October 2006). «Genetic and epigenetic biomarkers in cancer diagnosis and identifying high risk populations.». Critical Reviews in Oncology/Hematology 60 (1): 9-18. PMID 16829121. doi:10.1016/j.critrevonc.2006.04.002.
«Distinguishing second primary tumors from lung metastases in patients with head and neck squamous cell carcinoma.». Journal of the National Cancer Institute 90 (13): 972-7. 1 de julio de 1998. PMID 9665144. doi:10.1093/jnci/90.13.972.
«High levels of serum TIMP-1 correlate with advanced disease and predict for poor survival in patients with multiple myeloma treated with novel agents». Leukemia Research 34 (3): 399-402. March 2010. PMID 19781774. doi:10.1016/j.leukres.2009.08.035.
«Loss of estrogen receptor in recurrent breast cancer is associated with poor response to endocrine therapy.». Journal of Clinical Oncology 14 (9): 2584-9. September 1996. PMID 8823339. doi:10.1200/jco.1996.14.9.2584.
«American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer.». Journal of Clinical Oncology 25 (33): 5287-312. 20 de noviembre de 2007. PMID 17954709. doi:10.1200/JCO.2007.14.2364.
«Prognostic and predictive effects of immunohistochemical factors in high-risk primary breast cancer patients.». Clinical Cancer Research 12 (1): 159-68. Jan 1, 2006. PMID 16397038. doi:10.1158/1078-0432.CCR-05-1340.
«Current and future anti-HER2 therapy in breast cancer.». Journal of the Balkan Union of Oncology 18 (1): 4-16. Jan–Mar 2013. PMID 23613383.
«Efficacy, safety, and pharmacokinetics of imatinib dose escalation to 800 mg/day in patients with advanced gastrointestinal stromal tumors.». Investigational New Drugs 31 (5): 1367-74. Apr 17, 2013. PMID 23591629. doi:10.1007/s10637-013-9961-8.
«Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial.». Lancet 368 (9544): 1329-38. 14 de octubre de 2006. PMID 17046465. doi:10.1016/S0140-6736(06)69446-4.
«TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer.». Journal of Clinical Oncology 23 (25): 5892-9. 1 de septiembre de 2005. PMID 16043829. doi:10.1200/JCO.2005.02.840.
«Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.». The New England Journal of Medicine 350 (21): 2129-39. 20 de mayo de 2004. PMID 15118073. doi:10.1056/NEJMoa040938.
Sawyers CL (April 2008). «The cancer biomarker problem». Nature 452 (7187): 548-52. PMID 18385728. doi:10.1038/nature06913.
«Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyltransferase gene locus». Journal of the National Cancer Institute 91 (23): 2001-8. December 1999. PMID 10580024. doi:10.1093/jnci/91.23.2001.
«Serum S100--a marker for disease monitoring in metastatic melanoma.». Dermatology 194 (3): 208-12. 1997. PMID 9187834. doi:10.1159/000246103.
«S100 proteins as cancer biomarkers with focus on S100B in malignant melanoma.». Clinical Biochemistry 37 (7): 512-8. July 2004. PMID 15234232. doi:10.1016/j.clinbiochem.2004.05.012.
«Is the 21-gene recurrence score a cost-effective assay in endocrine-sensitive node-negative breast cancer?». Expert Review of Pharmacoeconomics & Outcomes Research 13 (2): 243-50. April 2013. PMID 23570435. doi:10.1586/erp.13.4.
«Impact of Oncotype DX on Treatment Decisions in ER-Positive, Node-Negative Breast Cancer with Histologic Correlation.». The Breast Journal 19 (3): 269-75. May 2013. PMID 23614365. doi:10.1111/tbj.12099.
«Imatinib: a review of its use in chronic myeloid leukaemia.». Drugs 67 (2): 299-320. 2007. PMID 17284091. doi:10.2165/00003495-200767020-00010.
«Gastrointestinal stromal tumor markers in cutaneous melanomas: relationship to prognostic factors and outcome». American Journal of Clinical Pathology 136 (1): 74-80. July 2011. PMID 21685034. doi:10.1309/AJCP9KHD7DCHWLMO.
«Chronic lymphocytic leukaemia CD20 expression is dependent on the genetic subtype: a study of quantitative flow cytometry and fluorescent in-situ hybridization in 510 patients». British Journal of Haematology 141 (1): 36-40. April 2008. PMID 18324964. doi:10.1111/j.1365-2141.2008.07012.x.
«Effective therapy of murine models of human leukemia and lymphoma with radiolabeled anti-CD30 antibody, HeFi-1». Proceedings of the National Academy of Sciences of the United States of America 104 (20): 8444-8. May 2007. PMC 1895969. PMID 17488826. doi:10.1073/pnas.0702496104.
«FIP1L1/PDGFRalpha synergizes with SCF to induce systemic mastocytosis in a murine model of chronic eosinophilic leukemia/hypereosinophilic syndrome». Blood 112 (6): 2500-7. September 2008. PMID 18539901. doi:10.1182/blood-2007-11-126268.
Nimer SD (May 2008). «Myelodysplastic syndromes». Blood 111 (10): 4841-51. PMID 18467609. doi:10.1182/blood-2007-08-078139.
«Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a phase 2 study». Blood 110 (7): 2309-15. October 2007. PMID 17496201. doi:10.1182/blood-2007-02-073528.
«Chemotherapeutic agents circumvent emergence of dasatinib-resistant BCR-ABL kinase mutations in a precise mouse model of Philadelphia chromosome-positive acute lymphoblastic leukemia». Blood 117 (13): 3585-95. March 2011. PMC 3072880. PMID 21263154. doi:10.1182/blood-2010-08-301267.
«Regulation of S100A10 by the PML-RAR-α oncoprotein». Blood 117 (15): 4095-105. April 2011. PMID 21310922. doi:10.1182/blood-2010-07-298851.
«A personalized approach to cancer treatment: how biomarkers can help». Clinical Chemistry 54 (11): 1770-9. November 2008. PMID 18801934. doi:10.1373/clinchem.2008.110056.
«Pharmacogenetic study in Hodgkin lymphomas reveals the impact of UGT1A1 polymorphisms on patient prognosis». Blood 113 (14): 3307-13. April 2009. PMID 18768784. doi:10.1182/blood-2008-03-148874.
«Evaluation of EML4-ALK fusion proteins in non-small cell lung cancer using small molecule inhibitors». Neoplasia 13 (1): 1-11. January 2011. PMC 3022423. PMID 21245935. doi:10.1593/neo.101120.
«New driver mutations in non-small-cell lung cancer». Lancet Oncology 12 (2): 175-80. February 2011. PMID 21277552. doi:10.1016/S1470-2045(10)70087-5.

oxfordjournals.org

jnci.oxfordjournals.org

«Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyltransferase gene locus». Journal of the National Cancer Institute 91 (23): 2001-8. December 1999. PMID 10580024. doi:10.1093/jnci/91.23.2001.

pnas.org

Wang, Qing; Raghothama Chaerkady (December 2010). «Mutant proteins as cancer-specific biomarkers.». Proceedings of the National Academy of Sciences 108: 2444-2449. PMC 3038743. PMID 21248225. doi:10.1073/pnas.1019203108. Consultado el 10 de abril de 2016.
«Effective therapy of murine models of human leukemia and lymphoma with radiolabeled anti-CD30 antibody, HeFi-1». Proceedings of the National Academy of Sciences of the United States of America 104 (20): 8444-8. May 2007. PMC 1895969. PMID 17488826. doi:10.1073/pnas.0702496104.

researchadvocacy.org

«Biomarkers in Cancer: An Introductory Guide for Advocates». Research Advocay Network. 2010. Archivado desde el original el 29 de octubre de 2013. Consultado el 26 de abril de 2013.

singularityhub.com

Hewes, Arlington (2 de octubre de 2014). «Promising Method for Detecting Pancreatic Cancer Years Before Traditional Diagnosis». Singularity HUB. Consultado el 22 de abril de 2016.

time.com

«New Hope for Cancer». 28 de mayo de 2001. Archivado desde el original el 25 de abril de 2013. Consultado el 26 de abril de 2013.

web.archive.org

Rhea, Jeanne; Ross J. Molinaro (March 2011). «Cancer Biomarkers: Surviving the journey from bench to bedside». Medical Laboratory Observer. Archivado desde el original el 14 de octubre de 2013. Consultado el 26 de abril de 2013.
«Biomarkers in Cancer: An Introductory Guide for Advocates». Research Advocay Network. 2010. Archivado desde el original el 29 de octubre de 2013. Consultado el 26 de abril de 2013.
«New Hope for Cancer». 28 de mayo de 2001. Archivado desde el original el 25 de abril de 2013. Consultado el 26 de abril de 2013.
«Tumor Markers Fact Sheet» (PDF). American Cancer Society. Archivado desde el original el 5 de noviembre de 2012. Consultado el 14 de marzo de 2018.
Lenz, Heinz-Josef. EdBk.GI.Colo.04.pdf «Established Biomarkers in Colon Cancer» (PDF). American Society of Clinical Oncology’s 2009 Educational Book. (enlace roto disponible en Internet Archive; véase el historial, la primera versión y la última).